by Manon FRACHON | 7 Mar Tue | English
Noema Pharma’s clinical-stage assets and diversified pipeline hold significant potential in developing effective therapeutic options for patients with debilitating central nervous system (CNS) disorders, addressing high unmet medical needs Jeito Capital’s...
by Manon FRACHON | 6 Dec Tue | English
The Series C extension round will accelerate clinical development, manufacturing scale-up and pre-commercialization activities of Pulmocide’s lead product candidate, opelconazole. Paris, France, December 6th 2022 – Jeito Capital (“Jeito”), the...
by Manon FRACHON | 22 Nov Tue | English
Jeito Capital co-leads oversubscribed EUR 50 million Series C financing with Brandon Capital CatalYm is developing a new class of anti-cancer immunotherapies, which have already demonstrated initial promising clinical results in advanced-stage solid tumor patients...
by Manon FRACHON | 2 Nov Wed | English
Jeito Capital participates in $120 million financing alongside ARCH Venture Partners and Monograph Capital HI-Bio is a San Francisco-based clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases Investment...
by Manon FRACHON | 25 Oct Tue | English
Bastien Renaud is appointed Chief Financial Officer Evaldo Bifulco, Head of Compliance & Risk, and Charlotte Formont, Associate Counsel, also joined Jeito Capital in 2022 Paris, France, October 26, 2022 – Jeito Capital (“Jeito”), a leading...
Recent Comments